PMID- 37627625
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230828
IS  - 2076-3921 (Print)
IS  - 2076-3921 (Electronic)
IS  - 2076-3921 (Linking)
VI  - 12
IP  - 8
DP  - 2023 Aug 17
TI  - Melatonin as a Therapy for Preterm Brain Injury: What Is the Evidence?
LID - 10.3390/antiox12081630 [doi]
LID - 1630
AB  - Despite significant improvements in survival following preterm birth in recent 
      years, the neurodevelopmental burden of prematurity, with its long-term cognitive 
      and behavioral consequences, remains a significant challenge in neonatology. 
      Neuroprotective treatment options to improve neurodevelopmental outcomes in 
      preterm infants are therefore urgently needed. Alleviating inflammatory and 
      oxidative stress (OS), melatonin might modify important triggers of preterm brain 
      injury, a complex combination of destructive and developmental abnormalities 
      termed encephalopathy of prematurity (EoP). Preliminary data also suggests that 
      melatonin has a direct neurotrophic impact, emphasizing its therapeutic potential 
      with a favorable safety profile in the preterm setting. The current review 
      outlines the most important pathomechanisms underlying preterm brain injury and 
      correlates them with melatonin's neuroprotective potential, while underlining 
      significant pharmacokinetic/pharmacodynamic uncertainties that need to be 
      addressed in future studies.
FAU - Hausler, Silke
AU  - Hausler S
AD  - Division of Neonatology, Department of Pediatrics, Paracelsus Medical University 
      Salzburg, 5020 Salzburg, Austria.
FAU - Robertson, Nicola J
AU  - Robertson NJ
AD  - EGA Institute for Women's Health, University College London, London WC1E 6HX, UK.
AD  - Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, 49 Little 
      France Crescent, Edinburgh EH16 4SB, UK.
FAU - Golhen, Klervi
AU  - Golhen K
AUID- ORCID: 0009-0009-3738-7257
AD  - Pediatric Pharmacology and Pharmacometrics, University Children's Hospital Basel 
      (UKBB), University of Basel, 4001 Basel, Switzerland.
FAU - van den Anker, John
AU  - van den Anker J
AD  - Pediatric Pharmacology and Pharmacometrics, University Children's Hospital Basel 
      (UKBB), University of Basel, 4001 Basel, Switzerland.
AD  - Division of Clinical Pharmacology, Children's National Hospital, Washington, DC 
      20001, USA.
FAU - Tucker, Katie
AU  - Tucker K
AD  - EGA Institute for Women's Health, University College London, London WC1E 6HX, UK.
FAU - Felder, Thomas K
AU  - Felder TK
AUID- ORCID: 0000-0001-8266-5513
AD  - Department of Laboratory Medicine, Paracelsus Medical University, 5020 Salzburg, 
      Austria.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230817
PL  - Switzerland
TA  - Antioxidants (Basel)
JT  - Antioxidants (Basel, Switzerland)
JID - 101668981
PMC - PMC10451719
OTO - NOTNLM
OT  - encephalopathy of prematurity
OT  - inflammation
OT  - melatonin
OT  - neuroprotection
OT  - oligodendrocyte dysmaturation
OT  - oxidative stress
OT  - preterm infants
COIS- The authors declare no conflict of interest.
EDAT- 2023/08/26 10:44
MHDA- 2023/08/26 10:45
PMCR- 2023/08/17
CRDT- 2023/08/26 01:07
PHST- 2023/07/11 00:00 [received]
PHST- 2023/07/28 00:00 [revised]
PHST- 2023/08/15 00:00 [accepted]
PHST- 2023/08/26 10:45 [medline]
PHST- 2023/08/26 10:44 [pubmed]
PHST- 2023/08/26 01:07 [entrez]
PHST- 2023/08/17 00:00 [pmc-release]
AID - antiox12081630 [pii]
AID - antioxidants-12-01630 [pii]
AID - 10.3390/antiox12081630 [doi]
PST - epublish
SO  - Antioxidants (Basel). 2023 Aug 17;12(8):1630. doi: 10.3390/antiox12081630.